Canada's decision to override a patent on the anti-anthrax drug Cipro angered officials with German drugmaker Bayer AG, who said Friday they were seeking talks with the country's ministry of health. Canadian health officials said Thursday they would order stocks of the antibiotic from a Canadian manufacturer despite Bayer's patent on the antibiotic, which runs out in late 2003.